Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear.

Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, double-blind, phase 3 ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

More patients with eosinophilic esophagitis experienced a histologic response with benralizumab (Fasenra) compared with placebo, despite similar levels of continuing symptoms in the two groups at ...

Please provide your email address to receive an email when new articles are posted on . Benralizumab induces depletion of eosinophils and mepolizumab reduces activation. The study followed ...

After three months of treatment, four times fewer people taking benralizumab had suffered an asthma or COPD attack, compared to people taking the steroid prednisolone. “This could be a game ...

People taking benralizumab were significantly less likely to need further treatment for their asthma or COPD symptoms, a major clinical trial has shown ...

(RTTNews) - Researchers at King's College London have found a new treatment for asthma attacks, which could be a "game-changer" for the patients. Lead investigator Prof Mona Bafadhel, of King's ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

FASENRA® (benralizumab) injection for subcutaneous use is approved for the treatment of adults with EGPA. For the treatment of EGPA, the recommended dosage of FASENRA is 30 mg (one injection ...

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...